Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Cash from Investing Activities (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Cash from Investing Activities for 6 consecutive years, with $17.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Investing Activities fell 34.88% to $17.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $42.9 million, a 113.58% increase, with the full-year FY2024 number at -$302.4 million, down 361.36% from a year prior.
  • Cash from Investing Activities was $17.8 million for Q3 2025 at 4D Molecular Therapeutics, up from -$13.9 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $57.5 million in Q2 2022 to a low of -$263.3 million in Q1 2024.
  • A 5-year average of -$17.9 million and a median of -$642000.0 in 2021 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: tumbled 39930.95% in 2021, then skyrocketed 7897.56% in 2022.
  • 4D Molecular Therapeutics' Cash from Investing Activities stood at -$32.3 million in 2021, then fell by 10.8% to -$35.8 million in 2022, then soared by 81.32% to -$6.7 million in 2023, then skyrocketed by 205.64% to $7.1 million in 2024, then surged by 151.85% to $17.8 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Cash from Investing Activities are $17.8 million (Q3 2025), -$13.9 million (Q2 2025), and $31.9 million (Q1 2025).